These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 23106204

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL.
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [Abstract] [Full Text] [Related]

  • 9. Simple case definition of clinical benign prostatic hyperplasia, based on International Prostate Symptom Score, predicts general practitioner consultation rates.
    Kok ET, Bohnen AM, Jonkheijm R, Gouweloos J, Groeneveld FP, Thomas S, Bosch JL.
    Urology; 2006 Oct; 68(4):784-9. PubMed ID: 17070353
    [Abstract] [Full Text] [Related]

  • 10. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH, Meehan A, Lee M, Penson DF, Wessells H.
    J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Consultation patterns in a community survey of men with benign prostatic hyperplasia.
    Simpson RJ, Lee RJ, Garraway WM, King D, McIntosh I.
    Br J Gen Pract; 1994 Nov; 44(388):499-502. PubMed ID: 7538316
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [Abstract] [Full Text] [Related]

  • 15. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK.
    J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
    [Abstract] [Full Text] [Related]

  • 16. Incidence rates and risk factors for acute urinary retention: the health professionals followup study.
    Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I.
    J Urol; 1999 Aug; 162(2):376-82. PubMed ID: 10411042
    [Abstract] [Full Text] [Related]

  • 17. Prevention of benign prostatic hyperplasia disease.
    Marks LS, Roehrborn CG, Andriole GL.
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [Abstract] [Full Text] [Related]

  • 18. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS, Roehrborn CG, Wolford E, Wilson TH.
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [Abstract] [Full Text] [Related]

  • 19. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [Abstract] [Full Text] [Related]

  • 20. [Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma].
    Madersbacher S.
    Wien Med Wochenschr; 2001 Jan; 151(18-20):430-8. PubMed ID: 11817252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.